Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Products under Development by Stage of Development | 8 | 1 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Products under Development by Therapy Area | 9 | 1 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Products under Development by Indication | 10 | 1 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Products under Development by Companies | 13 | 2 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Products under Development by Universities/Institutes | 15 | 2 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Companies Involved in Therapeutics Development | 23 | 8 |
| Alnylam Pharmaceuticals, Inc. | 23 | 1 |
| Arcturus Therapeutics, Inc. | 24 | 1 |
| Ionis Pharmaceuticals, Inc. | 25 | 1 |
| Neurimmune Holding AG | 26 | 1 |
| Pfizer Inc. | 27 | 1 |
| Prothena Corporation Plc | 28 | 1 |
| Regeneron Pharmaceuticals Inc | 29 | 1 |
| SOM Biotech SL | 30 | 1 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Drug Profiles | 31 | 26 |
| ALN-TTRsc02 Drug Profile | 31 | 1 |
| doxycycline hyclate Drug Profile | 32 | 1 |
| EDE-1307 Drug Profile | 33 | 1 |
| inotersen sodium Drug Profile | 34 | 4 |
| LUNAR-TTR Drug Profile | 38 | 1 |
| Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy Drug Profile | 39 | 1 |
| NI-301 Drug Profile | 40 | 1 |
| Oligonucleotides to Inhibit Transthyretin for Amyloidosis Drug Profile | 41 | 1 |
| patisiran Drug Profile | 42 | 8 |
| PRX-004 Drug Profile | 50 | 1 |
| Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy Drug Profile | 51 | 1 |
| tafamidis meglumine Drug Profile | 52 | 3 |
| tolcapone Drug Profile | 55 | 2 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Dormant Projects | 57 | 1 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Discontinued Products | 58 | 1 |
| Transthyretin (ATTR or Prealbumin or TBPA or TTR) Featured News &Press Releases | 59 | 17 |
| Oct 10, 2016: Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) | 59 | 1 |
| Aug 08, 2016: Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease | 59 | 1 |
| Jul 07, 2016: Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis | 60 | 2 |
| Jul 01, 2016: Alnylam Reports New Results on patisiran at the XV International Symposium on Amyloidosis | 62 | 2 |
| Jun 27, 2016: Alnylam to Report New Patisiran Results at the XV International Symposium on Amyloidosis | 64 | 1 |
| Jun 09, 2016: Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis | 65 | 1 |
| May 26, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program | 65 | 1 |
| Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) | 66 | 2 |
| Apr 07, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program | 68 | 1 |
| Mar 16, 2016: Data from Prothena's Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid | 69 | 1 |
| Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) | 69 | 1 |
| Dec 17, 2015: Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis | 70 | 1 |
| Nov 12, 2015: SOM Biotech and Vall d Hebron successfully complete a clinical trial in patients with TTR amyloidosis | 71 | 1 |
| Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Patisiran in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) | 72 | 2 |
| Nov 03, 2015: Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented at the EC-ATTR Meeting | 74 | 2 |
| Appendix | 76 | 2 |
| Methodology | 76 | 1 |
| Coverage | 76 | 1 |
| Secondary Research | 76 | 1 |
| Primary Research | 76 | 1 |
| Expert Panel Validation | 76 | 1 |
| Contact Us | 76 | 1 |
| Disclaimer | 77 | 1 |
